Assessment of Off-label Prescribing Compared With FDA-Approved Treatment With Combined Dextromethorphan and Quinidine in 2 Commercial Insurance Databases

IMPORTANCE: In 2010, the US Food and Drug Administration approved a combination of dextromethorphan hydrobromide and quinidine sulfate with an Orphan Drug Act designation for the treatment of pseudobulbar affect in patients with amyotrophic lateral sclerosis (ALS) or multiple sclerosis (MS). This me...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:JAMA Intern Med
Huvudupphovsmän: Fralick, Michael, Sacks, Chana A., Kesselheim, Aaron S.
Materialtyp: Artigo
Språk:Inglês
Publicerad: American Medical Association 2018
Ämnen:
Original Investigation
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC6142962/
https://ncbi.nlm.nih.gov/pubmed/30039158
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamainternmed.2018.3016
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk